Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The Price of National Pharmaceutical Pricing in the EU: A Proposal for "Common Procurement".Applied health economics and health policy · 2026
   Review
2. Collaborating for Affordable Patient Access to Medicines: Review of the First Decade of the Beneluxa Initiative in Pharmaceutical Policy.Applied health economics and health policy · 2026
   Review
3. The impacts of pricing and reimbursement policies on access to cell and gene therapies across Europe.Journal of community genetics · 2026
   Review
4. Parental preferences for generic substitution policies for children in China: a discrete choice experiment.BMJ open · 2026
   Article
5. Policies to promote affordability and access across the life cycle of costly new drugs.BMJ (Clinical research ed.) · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.